DUBLIN–(BUSINESS WIRE)–The “The Biosimilars Landscape in Japan: 2009-2020 Study” report has been added to ResearchAndMarkets.com’s offering.
Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and attained annual sales of ~32.4b ($300m).
Despite the string of recent biosimilars approvals, healthcare professionals still harbor concerns over the quality of biosimilars.
Since the last five years, most of the companies have some alliance in place for biosimilars, with most of the Japanese companies undertaking pacts with South Korean companies to ride on their back of biosimilar mAb expertise.
There is a trend of doing product specific alliance by most of the JP companies active in BS space and to go step by step on this high risk/high return opportunities. Against this backdrop, multinational companies like Pfizer are setting their sights on this market without local partnership taking advantage of pro-biosimilar environment to capture decent biosimilar market share. Overall, in the Japan market, each opportunity has a different competitive landscape for itself, and some companies are looking for niche opportunities in biosimilar space as per their specialty therapy area- like ophthalmology BS (Lucentis), Enzyme therapy BS (JCR).
While launched biosimilars now generates ~32b ($300m) sales and its penetration is accelerating, MHLW’s approval of “Biosame” of NESP based on same clinical data as the originator NESP, and current ongoing dialogs to price “Biosame” higher than biosimilars, indicative of Biosame to be the key hurdle in the future for mid-size biosimilar companies in Japan. In the year 2020, MHLW’s stand on Biosame, will be important to decide future of theses mid-size /generic biosimilar developers. Around ~550b opportunity is opening for biosimilar in the next 7 years in Japan due to patent expiry of Wave 2-3 biologics.
This report analyzes trend/requirement of regulatory approval of biosimilars based on Ex-Japan clinical trial data, factors responsible for each key launched biosimilar penetration (“Made in Japan” vs. “Tested by Japan”), and the future competitive landscape in the biosimilars space in Japan.
It analyzes BS market of EPO, Filgrastim/Pegfilgrastim/ Insulin/Lantus apart from other key complex Mab Biosimilar opportunities and lists out niche opportunities in biosimilar space in Japan. Details of all major consolidation activities done by JP/Foreign companies in biosimilar space in the last five years and crisp summary on strategies of each key player (~21 JP local companies, multinational companies), their interest & focus for future collaboration in biosimilar space.
Key Topics Covered:
CHAPTER 1: EXECUTIVE SUMMARY
CHAPTER 2: JAPANESE GOVERNMENT AND “CHUIKYO” INITIATIVES TO INCREASE BIOSIMILAR PENETRATION IN JAPAN
CHAPTER 3: LESSONS FROM LAUNCHED BIOGENERIC PROGRESS IN JAPAN SINCE 2009
CHAPTER 4: GROWTH HORMONE MARKET (SOMATROPIN) IN JAPAN
CHAPTER 5: ANEMIA MARKET IN JAPAN
CHAPTER 6: FILGRASTIM (GRAN) BS
CHAPTER 7: REMICADE (INFLIXIMAB) BS
CHAPTER 8: LANTUS (INSULIN GLARGINE) BIOSIMILAR
CHAPTER 9: ENBREL (ETANERCEPT) BIOSIMILAR
CHAPTER 10: ONCOLOGY BIOSMILARS ERA STARTS WITH RITUXAN (RITUXIMAB) BIOSIMILAR
CHAPTER 11: HERCEPTIN (TRASTUZUMAB) BIOSIMILAR
CHAPTER 12: AVASTIN (BEVACIZUMAB) BIOSIMILAR
CHAPTER 13: FABRAZYME (AGALSIDASE BETA) BIOSIMILAR
CHAPTER 14: FORTEO (TERIPARATIDE) BIOSIMILAR
CHAPTER 15: NEXT WAVE OF BIOSIMILAR OPPORTUNITIES IN JAPAN
CHAPTER 16: BIOSIMILAR/BIOPHARMA CMO OPPORTUNITY
CHAPTER 17: REGULATORY APPROVAL REQUIREMENT FOR COMPLEX MAB BIOSIMILAR IN JAPAN
CHAPTER 18: LICENSING/CONSOLIDATION ACTIVITIES IN BIOSIMILAR SPACE IN JAPAN
CHAPTER 19: JAPANESE COMPANIES ACTIVE INTO BIOGENERICS SPACE
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/y7ydvw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - The "Immersive Hong…
HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - The first baijiu…
The all-weather indoor sportainment complex, JOYPOLIS SPORTS HONG KONG, grandly opens today. With five stories…
"Global Multi-Currency Accounts" Empowers SMEs with New Market Opportunities SHANGHAI, CHINA - Media OutReach Newswire…
"Global Multi-Currency Accounts" Empowers SMEs with New Market Opportunities SHANGHAI, CHINA - Media OutReach Newswire…
GUANGZHOU, CHINA - Media OutReach Newswire - 20 December 2024 - This year marks the…
